drugset
drugset / Trial / NCT06944106

A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

NCT06944106 ↗

Phase 2 Recruiting 30 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This trial is a prospective, single-arm, single-center Phase II clinical study aimed at evaluating the efficacy and safety of Ivonescimab combined with the gemcitabine and nab-paclitaxel (AG) regimen as neoadjuvant therapy for borderline resectable pancreatic cancer.

Timeline

Start
2025-03-28
Primary completion
2026-04-28
Completion
2027-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody 20 mg/kg —
Background Gemcitabine Small molecule — —
Background Paclitaxel Small molecule — —

Indications

malignant pancreatic neoplasm